DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Budigalimab

Generic Name: Budigalimab

Drug Type: Biotech

CAS Number: 2098225-93-3

Unique Ingredient Identifier: 6VDO4TY3OO

Overview

Budigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis).

Background

Budigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab

Phase 1

Recruiting

Posted: 2021/08/13

Sponsor:AbbVie

Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)

Phase 1

Completed

Posted: 2021/03/16

Sponsor:AbbVie

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

Phase 1

Completed

Posted: 2020/01/10

Sponsor:AbbVie

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1

Completed

Posted: 2019/12/12

Sponsor:AbbVie

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Posted: 2019/03/28

Sponsor:AbbVie

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

AbbVie to Present Novel Cancer Therapies ABBV-969 and ABBV-514 at AACR Annual Meeting 2025

2 months ago

AbbVie will showcase data on ABBV-969, a first-in-class dual-targeted antibody-drug conjugate for metastatic castration-resistant prostate cancer, currently in Phase 1 clinical trials.

Trishula Therapeutics' TTX-030 Shows Promise in Phase I Pancreatic Cancer Trial

8 months ago

Trishula Therapeutics reported positive Phase I results for TTX-030, an anti-CD39 antibody, in first-line metastatic pancreatic cancer treatment.

Trishula Therapeutics' TTX-030 Shows Promise in Metastatic Pancreatic Cancer Phase 1 Trial

8 months ago

A Phase 1 trial of TTX-030 in first-line metastatic pancreatic cancer showed a median overall survival of 19.1 months in the efficacy-evaluable population.

Immunotherapy Advances Reshape Treatment Landscape for Small Cell Lung Cancer

8 months ago

Durvalumab consolidation post-chemoradiotherapy significantly improves overall and progression-free survival in limited-stage SCLC, marking a breakthrough in nearly three decades.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy